---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-082784"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:59:54.113998+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zymeworks removes CFO Christopher Astle; CEO Kenneth Galbraith named interim CFO

## Summary
- Dr. Christopher Astle removed as SVP and CFO, including principal financial and accounting officer, effective March 31, 2024.
- Kenneth Galbraith, Chair, President, and CEO, appointed interim CFO, assuming principal financial and accounting duties.
- Company has initiated a search for a new permanent CFO.
- Mr. Galbraith's compensation arrangements remain unchanged per prior filings.
- No family relationships or arrangements with other persons regarding the appointment.

## SEC filing metadata
- accession: 0001193125-24-082784
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312524082784/0001193125-24-082784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312524082784/d806103d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-082784
- JSON: https://secwatch.observer/filing/0001193125-24-082784.json
- Plain text: https://secwatch.observer/filing/0001193125-24-082784.txt

## Key facts
- Executive change
  Kenneth Galbraith was appointed as interim Chief Financial Officer at Zymeworks Inc..
  - Action: appointed
  - Role: interim Chief Financial Officer
  source text: the Company’s board of directors (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chair of the Board, President and Chief Executive Officer, as the Company’s interim Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000119312524082784/0001193125-24-082784-index.htm
- Executive change
  Dr. Christopher Astle was removed as Senior Vice President and Chief Financial Officer at Zymeworks Inc..
  - Action: removed
  - Role: Senior Vice President and Chief Financial Officer
  source text: On March 31, 2024, Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000119312524082784/0001193125-24-082784-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.